# New Science Ventures

> New Science Ventures is a VC fund backing Biotechnology and Health Care. See 87 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 87
- Last investment: Jul 2026
- Lead investor: 36%
- Fund size: $4.9M
- Last fund: Jan 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/659711?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A659711%2Cidx%3A1-1-1%2CtarId%3A1442949621645%2Ctas%3ANew%20Science%20Ventures
- Website: http://www.newscienceventures.com

New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.

## Contacts

5 contacts available for New Science Ventures. Shizune tracks 7 team members at New Science Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/new-science-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4M–$49M |
| Series B | $8M–$52M |
| Series D | $5M–$38M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 28% |
| Health Care | 19 | 22% |
| Medical | 11 | 13% |
| Therapeutics | 11 | 13% |
| Software | 9 | 10% |

65 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 23 | 26% |
| Series A | 18 | 21% |
| Series D | 9 | 10% |
| Series C | 8 | 9% |
| Funding Round | 8 | 9% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 45% |
| United Kingdom | 5 | 6% |
| Belgium | 4 | 5% |
| The Netherlands | 2 | 2% |
| France | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Somu Subramaniam | Co-Founder & Managing Partner | 16 | https://shizune.co/investors/profile/somu-subramaniam |
| Andrew Abrams | Vice President | 0 | https://shizune.co/investors/profile/andrew-abrams-e620 |
| Brenda Marex | CFO | 0 | https://shizune.co/investors/profile/brenda-marex |
| Jean-Pierre Bizet | Partner | 0 | https://shizune.co/investors/profile/jean-pierre-bizet |
| John Cecil | Partner | 0 | https://shizune.co/investors/profile/john-cecil-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Trellis Bioscience | Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $9M | Series C | Jul 16, 2026 |  |
| Glydways | Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $101.3M | Venture - Series Unknown | Sep 29, 2025 |  |
| Paragraf | Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $55M | Series C | Aug 25, 2025 |  |
| Pakal Technologies | Pakal Technologies is a developer of IGTO-based semiconductors intended to revolutionize the IGBT market. The company's semiconductors use IGTO, a silicon device, that is a drop-in replacement for IGBTs and provides a significant performance upgrade, providing clients with efficient, scalable, and compatible semiconductors. | $25M | Series B | Jan 29, 2025 |  |
| Glydways | Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $20M | Series B | May 14, 2024 |  |
| Glydways | Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $56M | Series B | Oct 05, 2023 |  |
| Vuv Analytics | VUV Analytics was incorporated in Austin, TX in December 2009, as a spin-off from a semiconductor equipment company. The five founders bring with them critical and unique know-how related to the hardware, software, analysis, intellectual property, and marketing associated with VUV technologies. The team's past success in pioneering VUVreflectometry for use in the semiconductor metrology field yielded several key market wins and an extensive IP portfolio, including 32 issued patents and 12 pending patents. | $20M | Venture - Series Unknown | Feb 16, 2023 |  |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M | Series B | Nov 03, 2022 |  |
| Morrow Optics | Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations.Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens.They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel.And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button.In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see. | $11M | Angel | Jul 18, 2022 |  |
| Morrow Optics | Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations.Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens.They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel.And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button.In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see. |  | Venture - Series Unknown | Jul 14, 2022 |  |

10 of 87 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 14 deals together
- [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 10 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 8 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 5 deals together
- [HLM Venture Partners](https://shizune.co/investors/profile/hlm-venture-partners) — VC Fund, 5 deals together
- [Oxford Bioscience Partners](https://shizune.co/investors/profile/oxford-bioscience-partners) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Consumer Investors in Belgium](https://shizune.co/investors/consumer-investors-belgium)
- [Consumer VC Funds in Belgium](https://shizune.co/investors/consumer-vc-funds-belgium)

## FAQ

### What does New Science Ventures invest in?

New Science Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 87 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is New Science Ventures's check size?

New Science Ventures typically joins rounds of $4M–$49M at Series A, $8M–$52M at Series B and $5M–$38M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Science Ventures participates in.

### How do I contact New Science Ventures?

Public channels for New Science Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at New Science Ventures?

The team at New Science Ventures includes Somu Subramaniam (Co-Founder & Managing Partner), Andrew Abrams (Vice President) and Brenda Marex (CFO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co